{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "BMY",
  "name": "Bristol-Myers Squibb Co.",
  "url": "https://frontierpicks.com/dossiers/BMY/",
  "json_url": "https://frontierpicks.com/dossiers/BMY.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Legacy-pharma re-rate off the 2026-07-30 guidance reset ($49.0–50.0B sales, $6.75–7.00 adj EPS) is intact, but both attention legs are spent: the AstraZeneca merger was denied 2026-08-05 and the FDA approved ZENBEXUS on 2026-08-13, four days early — and price still closed 2026-08-14 at $63.83, 3.1% under the high. Next dated company event is the 2026-09-30 Camzyos PDUFA.",
  "invalidation_trigger": "A daily close below $61 gives back the advance built off the 2026-07-30 FY2026 guidance raise; secondarily, the 2026-09-30 Camzyos adolescent PDUFA passing without approval removes the last dated pipeline event before the late-October Q3 print.",
  "catalyst_date": "2026-09-30",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "oncology-immunology",
    "m-and-a-special-situations",
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "ZENBEXUS carries accelerated approval only; BMS states full approval is contingent on verification of clinical benefit in confirmatory trial(s).",
    "Eliquis sits in the first CMS Medicare drug-price negotiation cohort, with negotiated prices effective 2026-01-01 — a permanent factor in the Eliquis revenue line.",
    "FDA target action dates are goals, not commitments. The 2026-09-30 Camzyos adolescent date can slip without a company announcement.",
    "The AstraZeneca combination was denied by Reuters on 2026-08-05. Recurring merger press is unconfirmed absent a filing or company statement.",
    "Next scheduled financial catalyst is the Q3 2026 print, expected late October 2026 — a long gap with no company-guided datapoints."
  ],
  "body_markdown": "\n​# BMY — Bristol-Myers Squibb Co.\n\n## Current Thesis\n\nThe narrative leg is unchanged in kind and changed in condition: a legacy-pharma re-rating built on the 2026-07-30 Q2 print (adjusted EPS $2.04 vs $1.59 consensus, revenue $12.973B vs $11.745B) and a FY2026 guidance reset whose new sales floor of $49.000B sits above the old $47.500B ceiling. Since the last note, both attention legs resolved. The AstraZeneca combination was denied by Reuters on 2026-08-05. The FDA binary resolved early and in the company's favour: accelerated approval of ZENBEXUS (iberdomide) with daratumumab and hyaluronidase-fihj and dexamethasone on 2026-08-13, four days ahead of the 2026-08-17 target action date.\n\nPrice did not extend on it. The 2026-08-14 close of $63.83 is below the $64.72 close of 2026-08-07 cited in the prior note and 3.1% under the $65.89 52-week high, with RSI(14) at 55.8 against 71.9 a week earlier. A favourable regulatory outcome absorbed without a new high, into a six-week stretch with no company-guided datapoint, is what a maturing narrative looks like on the tape.\n\n## Bull Case\n\n- **First-in-class approval, delivered ahead of schedule.** ZENBEXUS is the first cereblon E3 ligase modulator (CELMoD) approved, cleared 2026-08-13 for multiple myeloma as early as first relapse. EXCALIBER-RRMM showed MRD-negative complete response of 41% in the ZDd arm (n=207) versus 21% for DVd (n=213), p<0.0001, at 16 months median follow-up (BMS release, 2026-08-13). It is also among the first US approvals in relapsed/refractory myeloma granted on an MRD-negativity endpoint.\n- **The FY2026 raise was structural, not a single-quarter beat.** On 2026-07-30 sales guidance went to $49.000–50.000B from $46.000–47.500B (consensus $47.472B) and adjusted EPS to $6.75–7.00 from $6.05–6.35 (consensus $6.34).\n- **Mix shift is measurable.** Q2 2026 growth-portfolio revenue $7.6B, +14% YoY, approaching 60% of total; Camzyos $416M (+59%), Cobenfy $63M (+81%), Qvantig $261M, Breyanzi +41%, Reblozyl +29% (Q2 call, 2026-07-30).\n- **Eliquis FY2026 growth outlook raised to 20–25% from 10–15%**, against negotiated CMS prices effective 2026-01-01.\n- **A dated pipeline event survives the window.** Camzyos adolescent sNDA (ages 12 to <18, symptomatic oHCM, SCOUT-HCM: mavacamten n=23 vs placebo n=21, primary endpoint met on Valsalva LVOT gradient at week 28) carries a PDUFA date of 2026-09-30.\n- **Capital deployment into US manufacturing.** $2.3B Houston campus announced 2026-08-10, roughly 500 jobs — relevant to the pharma-tariff overhang that has repriced the cohort twice in the past year.\n\n## Bear Case\n\n- **The positive binary produced no new high.** Approval landed 2026-08-13; the 2026-08-14 close was $63.83, still 3.1% below the $65.89 52-week high set before it.\n- **ZENBEXUS is accelerated, not full, approval.** BMS states full approval is contingent on verification of clinical benefit in confirmatory trial(s); progression-free survival, the co-primary endpoint of EXCALIBER-RRMM, has not read out. A negative PFS result is a withdrawal risk, not merely a sentiment risk.\n- **Camzyos now has a launched competitor and a live lawsuit.** Cytokinetics filed a declaratory-judgment action in D. Delaware against BMS and MyoKardia on 2026-08-13 over US Patent No. 12,616,697, seeking non-infringement and invalidity plus an injunction barring BMS from threatening litigation over MYQORZO (aficamten). Camzyos is the fastest-scaling growth asset in the portfolio; its competitive setting is now contested in court.\n- **Consensus targets sit at spot.** MarketBeat's aggregate as of 2026-08-13 shows an average target of $64.92 against a $40–$75 range — roughly 1.7% implied from the $63.83 close. Two of the eight post-print anchors (RBC $64, Cantor $59, both 2026-07-31) are at or below it.\n- **Reported growth was +5.7% YoY** despite the ~10% revenue beat; the surprise measured the bar.\n- **Patent arithmetic past FY2026 is unresolved** and nothing dated inside this window speaks to it.\n\n## Setup & Price Structure\n\nThe narrative is **maturing**. The dates that justify the label: attention peaked 2026-08-02/03 on the $400B merger report and was denied 2026-08-05; the guidance raise of 2026-07-30 is now three weeks old and fully in the sell-side numbers; the 2026-08-13 approval was the last dated company event, and it cleared without a breakout. The narrative still works — 3-month return +13.3%, price within 3.1% of the high — but new information arriving per unit of time has fallen sharply, which is moderating flow rather than fresh participation.\n\nCrowding and positioning observables, stated as observables:\n- RSI(14) decayed from 71.9 (2026-08-07) to 55.8 (2026-08-14) while price fell from $64.72 to $63.83 — the momentum unwound faster than the price.\n- Average analyst target $64.92 versus a $63.83 close (MarketBeat aggregate, 2026-08-13): the sell-side anchor is at market, with the bull cluster at $73–75 (JPMorgan $73, Guggenheim $75, Argus $75) and the bear anchor at $40.\n- Retail-facing coverage clustered on 2026-08-02/03 around a merger that Reuters says never existed; that cohort's exit is untracked.\n- No earnings date inside 30 days; Q3 2026 is expected late October.\n- No Form 4 or registration activity appeared in the filing feed reviewed for the trailing 30 days — no insider-selling or issuance-into-strength signal either way, which is an absence of evidence, not evidence of absence.\n\nStructure to watch: the $61 area marks where the advance built off the 2026-07-30 guidance raise would be given back; the $65.89 high is the level a re-acceleration has to take out.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-16 to 2026-09-15 — no confirmed company-specific event.** This is the notable feature of the calendar: the two events that carried the tape (merger report, FDA action) are both resolved.\n- **2026-09-30 — PDUFA date, Camzyos (mavacamten) sNDA for adolescents 12 to <18 with symptomatic obstructive HCM.** Priority Review; SCOUT-HCM met its primary endpoint.\n- **~2026-10-29 (est.) — Q3 2026 results.** First independent check on the $49.000–50.000B / $6.75–7.00 FY ranges, on the 20–25% Eliquis growth outlook, and the first opportunity for a ZENBEXUS launch datapoint.\n\n## What Would Change Our Mind\n\nThe structural claim is that the 2026-07-30 guidance reset marks a durable step-up in run-rate rather than first-half timing. What would falsify it, in order of how directly it reads: FY2026 sales guidance walked back toward $46.000–47.500B at the Q3 print, or implied H2 revenue below the Q2 $12.973B run-rate; the Eliquis 20–25% growth range trimmed; management framing 2027 as a step-down year.\n\nOn price, a daily close below $61 gives back the post-guidance-raise advance and returns the discussion to loss-of-exclusivity math with no dated catalyst to interrupt it. A second condition: the 2026-09-30 Camzyos adolescent PDUFA passing without approval removes the last dated pipeline event before late October, leaving the name to trade on cohort beta and drug-pricing headlines.\n\nA separate falsifier runs the other way and would require re-rating the bull case upward: a confirmatory EXCALIBER-RRMM PFS result converting ZENBEXUS to full approval, or a first ZENBEXUS revenue line at the Q3 print that scales like Camzyos did.\n\n## Correlation Notes\n\n- Large-cap pharma cohort beta: moves with LLY, MRK, PFE, ABBV and the XLV/IHE complex on drug-pricing and tariff headlines. The 2026-08-10 $2.3B Houston commitment is a company-specific hedge against that shared exposure.\n- Eliquis sits in the first CMS negotiation cohort with prices effective 2026-01-01, so BMY carries above-cohort sensitivity to any Medicare pricing headline.\n- Camzyos and Cytokinetics' aficamten now trade as an explicit pair on the same patent docket (D. Del., filed 2026-08-13); adverse rulings for one are relevant to the other.\n- Recurring AstraZeneca merger press reintroduces correlation to the pharma M&A basket without any confirmed transaction behind it.\n- Effectively no correlation to the AI/semis complex; on risk-off days the name has traded with the defensive dividend cohort rather than the tape.",
  "first_seen": "2026-08-03",
  "last_analyzed": "2026-08-16T17:20:08+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}